1. Home
  2. SMHI vs IPHA Comparison

SMHI vs IPHA Comparison

Compare SMHI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEACOR Marine Holdings Inc.

SMHI

SEACOR Marine Holdings Inc.

HOLD

Current Price

$7.55

Market Cap

212.7M

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.79

Market Cap

189.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMHI
IPHA
Founded
1989
1999
Country
United States
France
Employees
N/A
163
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
212.7M
189.5M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
SMHI
IPHA
Price
$7.55
$1.79
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
130.2K
11.7K
Earning Date
04-29-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
62.41
N/A
EPS
N/A
N/A
Revenue
$173,783,000.00
N/A
Revenue This Year
$1.21
$180.36
Revenue Next Year
$9.31
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.70
$1.18
52 Week High
$8.17
$2.63

Technical Indicators

Market Signals
Indicator
SMHI
IPHA
Relative Strength Index (RSI) 53.20 52.34
Support Level $6.92 $1.73
Resistance Level $7.69 $1.98
Average True Range (ATR) 0.51 0.08
MACD 0.03 -0.00
Stochastic Oscillator 68.95 36.15

Price Performance

Historical Comparison
SMHI
IPHA

About SMHI SEACOR Marine Holdings Inc.

Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that (i) deliver cargo and personnel to offshore installations, including offshore wind farms, (ii) assist offshore operations for production and storage facilities, (iii) provide construction, well work-over, offshore wind farm installation and decommissioning support and (iv) carry and launch equipment used underwater in drilling and well installation, maintenance, inspection and repair. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America, with the majority of revenue deriving from the Africa and Europe segment.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: